DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Pharmacogenetics and Genomics

Volumn 16, Issue 12, 2006, Pages 901-910

  Morton, Lindsay M ^a   Wang, Sophia S ^a   Bergen, Andrew W ^a   Chatterjee, Nilanjan ^a   Kvale, Paul ^b   Welch, Robert ^a   Yeager, Meredith ^a   Hayes, Richard B ^a   Chanock, Stephen J ^a   Caporaso, Neil E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Alcohol consumption; Dopamine; Obesity; Smoking; Smoking cessation

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY WEIGHT; CIGARETTE SMOKING; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; OBESITY; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION;

AGED; ALCOHOL DRINKING; BODY MASS INDEX; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D2; REWARD; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; VARIATION (GENETICS);

EID: 33751105517     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000230417.20468.d0     Document Type: Article

References (38)

1. American Cancer Society. Cancer facts and figures, 2004. Atlanta, GA: American Cancer Society; 2004.
2. Gotay C. Behavior and cancer prevention. J Clin Oncol 2005; 23:301-310.
3. Cravchik A, Goldman D. Neurochemical individuality: genetic diversity among human dopamine and serotonin receptors and transporters. Arch Gen Psychiatry 2000; 57:1105-1114.
4. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003; 160:1041-1052.
5. Little HJ. Behavioral mechanisms underlying the link between smoking and drinking. Alcohol Res Health 2000; 24:215-224.
6. Volkow N, Wise R. How can drug addiction help us understand obesity? Nat Neurosci 2005; 8:555-560.
7. Di Chiara G, Bassareo V, Fenu S, De Luca M, Spina L, Cadoni C, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 2004; 47:227-241.
8. Bruijnzeel A, Markou A. Characterization of the effects of bupriopion on the reinforcing properties of nicotine and food in rats. Synapse 2003; 50: 20-28.
9. Epstein LH, Wright SM, Paluch RA, Leddy JJ, Hawk LW Jr, Jaroni JL, et al. Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers. Am J Clin Nutr 2004; 80:82-88.
10. Lerman C, Berrettini W, Pinto A, Patterson F, Crystal-Mansour S, Wileyto EP, et al. Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berlin) 2004; 174:571-577.
11. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685-691.
12. Heath AC, Bucholz K, Madden PA, Dinwiddie S, Slutske WS, Bierut LJ, et al. Genetic and environmental contributions to alcohol dependence risk in a national twin sample: consistency of findings in women and men. Psychol Med 1997; 27:1381-1396.
13. Schousboe K, Willemsen G, Kyvik K, Mortensen J, Boomsma DI, Cornes B, et al. Sex differences in heritability of BMI: a comparative study of results from twin studies in eight countries. Twin Res 2003; 6:409-421.
14. Heath AC, Martin NG. Genetic models for the natural history of smoking: evidence for a genetic influence on smoking persistence. Addict Behav 1993; 18:19-34.
15. Clement K. Genetics of human obesity. Proc Nutr Soc 2005; 64:133-142.
16. Tyndale RF. Genetics of alcohol and tobacco use in humans. Ann Med 2003; 35:94-121.
17. Sullivan PF, Kendler KS. The genetic epidemiology of smoking. Nicotine Tob Res 1999; 1(Suppl 2):S51-S57; discussion S69-S70.
18. Munafo M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004; 6:583-597.
19. Prorok PC, Andriole G, Bresalier R, Buys S, Chia D, Crawford E, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21:273S-309S.
20. Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res 2005; 592:147-154.
21. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6:577-582.
22. Sarkar G, Kapelner S, Grandy DK, Marchionni M, Civelli O, Sobell J, et al. Direct sequencing of the dopamine D2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural change in the receptor. Genomics 1991; 11:8-14.
23. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003; 12:205-216.
24. Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, et al. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 1989; 45:778-785.
25. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006; 34:D617-D621.
26. Barrett J, Fry B, Maller J, Daly M. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
27. Spitz MR, Detry MA, Pillow P, Hu Y, Amos CI, Hong WK, et al. Variant alleles of the D2 dopamine receptor gene and obesity. Nutr Res 2000; 20: 371-380.
28. Pohjalainen T, Rinne J, Nagren K, Lehikoinen P, Anttila K, Syvalahti E, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3:256-260.
29. Hirvonen M, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. Erratum: C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 2005; 10:889.
30. Hirvonen M, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 2004; 9:1060-1061.
31. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004; 23:540-545.
32. Gelernter J, Goldman D, Risch N. The A1 allele at the D2 dopamine receptor gene and alcoholism. A reappraisal. JAMA 1993; 269:1673-1677.
33. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57:79-115.
34. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2001. MMWR 2003; 52:953-956.
35. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22:541-548.
36. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results from two randomized clinical trials. Neuropsychopharmacology 2006; 31:231-242.
37. Swan GE, Valdes A, Ring H, Khroyan T, Jack L, Ton C, et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 2005; 5:21-29.
38. Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004; 14:83-90.